Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma

تاریخ : ۱۳۹۲/۱۲/۲۰ / تعداد بازدید : ۲۳۳

Abstract

Purpose

Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O6-methylguanine-DNA methyltransferase (MGMT) methylation status may be an important determinant of treatment response. Dose-dense (DD) temozolomide results in prolonged depletion of MGMT in blood mononuclear cells and possibly in tumor. This trial tested whether DD temozolomide improves overall survival (OS) or progression-free survival (PFS) in patients with newly diagnosed GBM.

Patients and Methods

This phase III trial enrolled patients older than age 18 years with a Karnofsky performance score of 60 with adequate tissue. Stratification included clinical factors and tumor MGMT methylation status. Patients were randomly assigned to standard temozolomide (arm 1) or DD temozolomide (arm 2) for 6 to 12 cycles. The primary end point was OS. Secondary analyses evaluated the impact of MGMT status.

Results

A total of 833 patients were randomly assigned to either arm 1 or arm 2 (1,173 registered). No statistically significant difference was observed between arms for median OS (16.6 v 14.9 months, respectively; hazard ratio [HR], 1.03; P .63) or median PFS (5.5 v 6.7 months; HR, 0.87; P .06). Efficacy did not differ by methylation status. MGMT methylation was associated with improved OS (21.2 v 14 months; HR, 1.74; P .001), PFS (8.7 v 5.7 months; HR, 1.63; P .001), and response (P .012). There was increased grade 3 toxicity in arm 2 (34% v 53%; P .001), mostly lymphopenia and fatigue.

Conclusion

This study did not demonstrate improved efficacy for DD temozolomide for newly diagnosed GBM, regardless of methylation status. However, it did confirm the prognostic significance of MGMT methylation. Feasibility of large-scale accrual, prospective tumor collection, and molecular stratification was demonstrated.

click here for view full article: Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma

آخرین مقالات

ثبت مشخصات

نام

پست الکترونیک

کپچا

دیدگاه

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma

Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis

دانستنی های مفید در خصوص حساسیت دارویی

دلایل و درمان سرگیجه

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosi

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis